The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors

Now that atazanavir and darunavir can both be dosed as one pill once daily, which is the better choice for first-line antiretroviral therapy? Take our poll at HIV and ID Observations.

The FDA recently approved an 800-mg tablet of darunavir for treatment-naive patients, which means that atazanavir and darunavir now have the same pill burden (one pill once daily). In his blog HIV and ID Observations, Dr. Paul Sax does a point-by-point comparison of darunavir and atazanavir — which is the better first choice? Take our poll here.

Published in Journal Watch HIV/AIDS Clinical Care November 19, 2012

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Remark subject:*

Your remark:*

Fields marked with an * are required.

Name as you'd like it to appear:
First & middle initial:*

Last:*

Email address (will not
be published):*

Professional specialty:*

Place of work (optional):

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

No competing interests

Or, the following competing interests (for example, financial stakes or professional relationships):

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.